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Abstract: The family of matrix metalloproteinases (MMPs) consists of a set of biological targets that
are involved in a multitude of severe pathogenic events such as dierent forms of cancers or arthritis.
Modulation of the target class with small molecule drugs has not led to the anticipated success until
present, as all clinical trials failed due to unacceptable side eects or a lack of therapeutic outcome.
Monoclonal antibodies oer a tremendous therapeutic potential given their high target selectivity and
good pharmacokinetic profiles. For the treatment of a variety of diseases there are already antibody
therapies available and the number is increasing. Recently, several antibodies were developed for
the selective inhibition of single MMPs that showed high potency and were therefore investigated
in in vivo studies with promising results. In this review, we highlight the progress that has been
achieved toward the design of inhibitory antibodies that successfully modulate MMP-9 and MMP-14.
Keywords: inhibitory antibody; drug design; matrix metalloproteinase; tissue inhibitors of
metalloproteinases; selectivity
1. Introduction
Matrix metalloproteinases (MMPs) are zinc and calcium dependent endopeptidases that are
involved in tissue remodeling and other processes where the degradation of extracellular matrix (ECM)
proteins is involved. Due to their involvement in a variety of diseases, they have been of interest in
pharmaceutical research for decades [1–4]. Early attempts of inhibitor development focused on strong
metal chelators like hydroxamic acids that were able to block the catalytic center within the enzyme.
Even though the approach delivered highly potent inhibitors, none of them survived clinical trials as a
result of intolerable side eects like joint stiening [5]. As those early inhibitors did not distinguish
between individual MMPs but blocked the whole panel, further eorts were taken in the direction of
finding selective inhibitors for a particular MMP family member. By moving from strong zinc binding
groups, such as hydroxamic acids, to weaker chelators, such as carboxylic acids, the eect that zinc
binding has on enzyme inhibition could be reduced and the impact of the remaining interactions was
strengthened. As the three-dimensional structure of the active sites throughout the MMPs dier, this
development yielded modulators with a more sophisticated selectivity profile than the broad-spectrum
inhibitors. Further evolution targeting more selective inhibitors brought up allosteric binders that did
not interact with the catalytic zinc but blocked the enzyme in a non-competitive fashion. Over time,
selective inhibitors could be developed for many of the MMPs, but up to date none of them have
reached the market. All of them failed in clinical trials for dierent reasons such as side eects or lack
of the therapeutic eect. Those problems with small molecule inhibitors required new approaches to
be taken in the challenging field of finding a drug that targets this intriguing class of enzymes.
Antibodies represent a means of achieving a high degree of selectivity towards disease-causing
biological targets. They are involved in the immune response of an organism to neutralize pathogens,
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such as viruses and pathogenic bacteria, through binding to their surface with the antigen binding site
within the Fab region, as displayed in Figure 1 [6–8].
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targets in pathogenic events, can be blocked selectively with inhibitory antibodies [18–34]. This 
emerging field of interfering with single MMPs through inhibitory antibodies provides new options 
on the road to finally tackle MMP related diseases and get a corresponding drug on the market. 
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regulated by the tissue inhibitors of metalloproteinases (TIMPs) [43]. An imbalance in this system, 
leading to increased MMP activity, is associated with a multitude of severe diseases like cancer, 
arthritis, chronic obstructive pulmonary disease (COPD), or sepsis [36,44–58]. The general structure 
of the MMP family members is very similar and incorporates up to three Ca2+ ions and a Zn2+ ion as 
structural elements. A second Zn2+ ion within the catalytic domain, which is complexed by three 
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fatal. Other adverse events include cardiovascular and pulmonary problems, and cancer, for example,
that were reported to occur after administr tion of antibody drugs, forc ng the discontinuation of
the therapies [9,10]. Numerous targets inhibitory antibodies already exist hat proved to be eective
in vitro and in vivo [11–17]. On the matrix metalloproteinas pl tform, the gelatinase B (MMP-9) and
th membrane-type matrix metalloproteinase-1 (MMP-14), both validated targets in pathogenic events,
c n be blocked sel ct vely with inhi itory antibodi s [18–34]. T is emerging field of interfering with
single MMPs through inh bitory antibodies provides new options on the road to finally tackle MMP
rela ed diseases and get a corresponding drug on the market.
2. atrix etallo rotei ases
atrix metalloproteinases (M Ps) are proteolytic enzymes found in healthy organisms where they
are involved in physiological processes like angiogenesis, wound healing, and embryonic development,
as well as in regulating inflammatory processes [35–42]. Their activity is strongly regulated by the
tissue inhibitors of metalloproteinases (TIMPs) [43]. An imbalance in this system, leading to increased
MMP activity, is associated with a multitude of severe diseases like cancer, arthritis, chronic obstructive
pulmonary disease (COPD), or sepsis [36,44–58]. The general structure of the MMP family members is
very similar and incorporates up to three Ca2+ ions and a Zn2+ ion as structural elements. A second
Zn2+ ion within the catalytic domain, which is complexed by three histidines, forms the active center
where protein hydrolysis takes place, using a water molecule. As MMPs are able to decompose proteins,
including themselves through autoproteolysis, they are expressed as inactive zymogens where the
catalytic center is complexed with a single cysteine residue of the propeptide domain. To obtain
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catalytic activity, the complex has to be dissociated through a “cysteine switch”, enabling a water
molecule to coordinate to the catalytic zinc [59].
2.1. Classes
MMPs can be divided into two main groups according to whether they are secreted to the
extracellular matrix (ECM) or anchored to the cell surface. Further, they are classified according to their
preferential substrate: The collagenases (MMP-1, -8, -13, -18), gelatinases (MMP-2, -9), stromelysins
(MMP-3, -10, -11), MT-MMPs (MMP-14, -15, -16, -17, -24, -25), and others (MMP-7, -12, -19, -20, -21, -22,
-23) together have the ability to decompose all components embodied in the extracellular matrix.
A challenge for pharmaceuticals targeting MMP-related diseases lies in the high redundancy
within the MMP network. If one MMP is selectively inhibited or knocked-out in an animal model,
other MMPs might step into action and compensate for the lack in function. This can be traced back to
the fact that each MMP in the network can hydrolyze multiple substrates and dierent substrates can
be cleaved by various MMPs. In a MMP-13 knock-out mice model, for example, enhanced MMP-8
expression was observed during wound healing [60]. An increase in MMP-9 expression was observed
in a MMP-8 deficient wound repair model [61]. This redundancy might be a possible explanation for
the unsatisfying outcome in clinical trials with selective MMP inhibitors so far.
2.2. Mechanism of Cleavage
The mechanism by which metalloenzymes degrade their substrates has been examined for decades
for several enzyme classes [62–64]. Evans and Cravatt have extensively reviewed a wide spectrum of
enzyme families and their mechanism of action [65]. A widely accepted mechanism was postulated by
Matthews for thermolysin and related zinc peptidases [66].
The incoming substrate drives the catalytic, zinc-bound water towards Glu270. The water oxygen
ligated to the zinc ion, as shown in Figure 2a, has enhanced nucleophilicity by having both its protons
hydrogen bonded to Glu270. Glu270 and zinc promote the attack of water on the carbonyl carbon of the
substrate, as shown in Figure 2b. Glu270 accepts a proton from the water molecule and immediately
shuttles it to the amide nitrogen at the scissile peptide bond of the substrate, as depicted in Figure 2c.
The collapse of the intermediate, displayed in Figure 2d, delivers the hydrolyzed products.
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Figure 2. Proposed echanis for the catalyzed hydrolysis of peptide bonds by carboxypeptidase A:
(a) nucleophilic attack of the ater olecule, (b) proton transfer to the substrate, (c) collapse of the
intermediate results in (d) the formation of the products, zinc (II) ion depicted as gray sphere; based on
Matthews [66].
2.3. Structural St dies
The general co siti i ses c prises conserved units as well as
structural features onl fo i a fracti f l Ps share a pro-peptide domain of
approximately 80 amino acid residues in length, incorporating a PRCGXPD motif interacting with e
active s te zinc io to block the catalytic cen er in the i active pro-form f the enzyme. The r moval
of the interacting cyste e, referred to as the cy teine-switch, has to occur for the ac ivation of the
proteolytic activity [59]. MMP-2 and MMP-9 possess three fibronectin type II domains for the interaction
with the collagen [67] and MMP-23 has a cysteine rich domain [68]. With the exception of MMP-7,
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-23, and -26, all isoforms possess a C-terminal hemopexin-like domain composed of about 190 amino
acids [69]. Figure 3 summarizes the schematic composition of the MMPs.
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S1’ Pocket Comparison
Within the catalytic domain, all MMPs share a structural feature, which is important for the
recognition of the preferred substrate. The so called S1’ pocket is located in close proximity to the
catalytic zinc (II) ion and it varies in length and shape among the dierent MMPs (Figure 5).
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Figure 5. Sequence alignment of the S1’ pocket-forming residues of the MMPs, for which crystallographic
data is available. (PDB IDs: MMP-1 1HFC [74], MP-2 1QIB [75], P-3 1HY7 [76], MMP-7 2Y6D [77],
P-8 1I76 [78], P-9 4XCT [79], MP-10 3V96 [80], MMP-11 1HV5 [81], MMP-12 1Y93 [82],
MMP-13 5B5O [83], MMP-14 3MA2 [84], MMP-16 1RM8 [85]).
According to this variety, the MMPs can be grouped into members with a small (MMP-1, MMP-7,
MMP-11, and MMP-20), medium (MMP-2, MMP-8, MMP-9, MMP-12, MMP-14, and MMP-16),
and large (MMP-3, MMP-10, and MMP-13) S1’ pocket. Fabre et al. have reviewed the dynamics of this
structural entity for the design of selective small molecule MMP inhibitors [86]. The green marked
amino acids in Figure 5 make up the specificity loop in close proximity to the catalytic zinc(II) ion and
the amino acid in position 214 (orange, numbering according to full MMP-3) is located within the S1’
channel. For most MMP family members, this position is occupied by a Leucine, but MMP-1, MMP-7,
and MMP-11 possess an Arginine, a Tyrosine, and a Glutamine at this site. Given the steric demand of
the sidechains, the available space within the selectivity pocket is limited, resulting in shorter channels
for those members. The dierent sequences in various MMP S1’ channels and the resulting dierence
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in size, shape, and surface property results in substrate specific recognition and simultaneously gives
an opportunity for the design of tailor-made selective inhibitors against a certain MMP.
3. MMP Inhibition
In healthy organisms, MMP activity is regulated by endogenous TIMPs that are natural inhibitors of
MMPs as well as of a disintegrin and metalloproteinases (ADAMs) and ADAMs with thrombospondin
motifs (ADAMTs) [87–89]. High TIMP levels lead to ECM accumulation due to inhibition of the
degradation processes, whereas low TIMP activity results in elevated proteolysis. All four members
of the TIMP family (TIMP-1, -2, -3, -4) inhibit the according enzyme by formation of stoichiometric
complexes [90,91]. Structurally, they consist of two distinct domains, an N-terminus of ~125 amino
acid residues and a C-terminus of ~65 amino acids in length [90]. Conformations characterized
by an elongated contiguous wedge consisting of the N-terminal segment, an all--structure motif,
and an all-helical center (Figure 6) are inherent throughout the TIMPs [90,91]. The function inhibiting
complexes of TIMPs with the MMPs are stabilized by interactions of the C-terminal domains of the
TIMPs with the hemopexin-like domain in most MMPs, and by interactions of the TIMPs N-terminal
domain with the zinc-ion within the catalytic domain of the MMPs [88–91]. Very recently, the Riedl
group analyzed such a MMP-TIMP complex and used it for the de novo design of highly potent and
selective MMP inhibitors [92].
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As an imbalance between MMPs and TIMPs plays a critical role in a variety of diseases,
the re-establishment of a balanced MMP activity profile delivers an approach for the development of
therapeutics [94–98]. Modulation of MMP activity can be achieved with TIMP analogues as described
by Arkadash et al. where they modified the non-specific N-TIMP-2 (N-terminal domain of TIMP-2)
to obtain a mutant that is highly potent against MMP-14 with a Ki of 0.9 pM and up to 16’000-fold
selectivity over other MMPs [99]. Further, peptidomimetics ith structural similarity to TIMPs showed
inhibition of selected MMPs with high potency and selectivity. Gall et al. described a cyclic TIMP
peptidomimetic for the inhibition of MMP-2, MMP-9, and MMP-13 (IC50 of 170 nM, 140 nM and
21 nM, respectively) [92]. Numerous small molecule inhibitors have been developed in the past for
the modulation of MMPs [1,100]. Early representatives inhibited all MMPs without discriminating
between the subtypes which led to undesired side eects and made the development of selective
inhibitors necessary. At present, there exist many small molecule inhibitors with a narrow spectrum
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or even selectivity for one specific MMP over all other family members. Nevertheless, so far, no
small molecule modulator of MMPs has emerged to the market as all failed in clinical trials due to
unsatisfying performance.
As the enzyme class is still an intriguing target in pharmaceutical research, novel strategies are
under investigation to modulate the MMP microenvironment. One technique that has already delivered
promising results is the engineering of inhibitory antibodies tailored to only block a single MMP.
4. Antibodies for MMP Inhibition
In addition to the aforementioned natural and synthetically obtained small molecule inhibitors,
there exists a third class of downregulating modulators of matrix metalloproteinases. Anti-MMP
antibodies can be designed and engineered for the selective inhibition of single MMP isoforms. Such
inhibitory antibodies have already been developed successfully for gelatinase B (MMP-9) as well as for
MT1-MMP (MMP-14) [23,24,28,30,101,102].
4.1. Anti-MMP-9 Antibodies
By producing human MMP-9 and using it as an antigen in a mouse, Paemen et al. prepared
mouse monoclonal antibodies (mAb) against gelatinase B [18]. Out of five selected antibodies with
variable epitope specificity and inhibitory activity, REGA-3G12 displayed superior properties in terms
of binding to both biotinylated as well as natural MMP-9, with a Kd of 2.1 nM. As none of the tested
antibodies showed cross-reactivity to the closely related MMP-2, they can be considered as selective
MMP-9 inhibitors. REGA-3G12 inhibited catalysis by gelatinase B in a degradation assay of nasal
septum type II gelatin and it inhibited the degradation of biotinylated gelatin in a solution assay [18].
Modifications of REGA-3G12 towards single-chain variable fragments (scFv) resulted in monomeric
forms that were all less active than the template antibody [21]. Further investigation on the mode of
inhibition revealed that REGA-3G12 interacts solely with the catalytic domain of MMP-9 and not with
the fibronectin repeats or the hemopexin domain (PDB not available). It recognizes the amino terminal
part and does not bind at the catalytic zinc-containing center. Those findings suggest that a part of the
catalytic domain (not the zinc-binding domain) can serve as target for the development of selective
inhibitors [22].
Recently, Sela-Passwell et al. have produced inhibitory antibodies with similar binding
mechanisms against gelatinases as the endogenous TIMPs [103]. Seeking an antibody that targets the
zinc(II) ion within the catalytic site, they have used a strategy in which mice were immunized with a
synthetic molecule mimicking the zinc–histidine complex, conserved in metalloenzymes. This set-up
yielded the function-blocking monoclonal antibodies SDS3 and SDS4 that inhibited MMP-9 and the
closely related MMP-2 (Ki values of 1 and 0.054 M for SDS3 and SDS4, respectively) while showing,
by an order of magnitude, lower inhibition of MMP-14 and sparing MMP-1, MMP-7, and MMP-12.
Surface plasmon resonance measurements of the antibodies showed that MMP-9 binding strongly
interfered in the presence of acetohydroxamic acid, suggesting a direct interaction between the
inhibitory antibodies and the catalytic zinc(II) ion in MMP-9. The antibodies bind their target MMPs
through protein–protein interactions with respect to the metal–protein motif, as well as to the enzyme
surface. Further selectivity towards a single MMP may be achieved by classical protein engineering
procedures that refine protein surface interactions between the antibody and the target enzyme [103].
Researchers at Gilead Sciences reported the development of Andecaliximab (GS-5745), a humanized
monoclonal antibody, as a potent (Kd = 0.168 nM) and highly selective allosteric inhibitor of the
gelatinase B (MMP-9) that spares MMP-1, -2, -3, -7, -8, -10, -12, -13, -14, and -16 with Kd-values of greater
than 100 nM [104]. As shown in the study, the selective inhibition of MMP-9 did not induce side eects
such as musculoskeletal syndrome, as was the case for broad-spectrum MMP inhibitors. In preclinical
investigations, MMP-9 inhibition reduced the disease severity in a mouse model of ulcerative colitis
and it decreased tumor growth and metastases incidence in a surgical orthotopic xenograft model of
Molecules 2019, 24, 2265 8 of 17
colorectal carcinoma. Further, it was shown that inhibition of either tumor, or stroma-derived MMP-9,
was sucient to reduce primary tumor growth [104].
Structural investigation revealed that GS-5745 binds MMP-9 distal to the active site, near the
junction between the prodomain and the catalytic domain, and inhibits MMP-9 by two mechanisms:
Binding to pro-MMP-9 prevents MMP-9 activation, whereas binding to active MMP-9 allosterically
inhibits activity [19]. For the recognition of MMP-9-pro-cat, an antibody fragment (Fab’) of GS-5745
was generated to facilitate structure determination. The fragment interacts with approximately 2130 Å2
of the enzyme surface and the formed complex is stabilized by hydrogen bonds with the glutamines
108, 126, 169, and 199 of MMP-9, one salt bridge to Arg162 of MMP-9, and hydrophobic interactions.
The nearest residue of GS-5745 is in approximately 17 Å distance to the active site zinc(II) ion so the
antibody does not occlude the catalytic site, which is in consistency with the proposed allosteric mode
of inhibition (Figure 7) [19].
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added toxicity [105]. Decreased free MMP-9 suggested inhibition of MMP-9 enzymatic activity
by GS-5745. A phase III study (NCT02545504) currently investigates the ecacy and safety of
GS-5745 combined with mFOLFOX6 in subjects with untreated gastric and gastroesophageal junction
adenocarcinoma [106].
For the treatment of inflammatory bowel disease complications with fibrosis, Gon et al.
investigated therapeutic ecacy of anti-MMP-9 antibodies [20]. It has been described that upregulation
of MMP-9 expression is observed in inflamed mucosa or serum of patients. The researchers generated
the anti-MMP-9 antibody CALY-001 and evaluated its ecacy in a mouse model of intestinal fibrosis
in comparison to AB-0046-h4, a potent and selective allosteric mouse monoclonal antibody against
MMP-9 that reduced disease severity in a dextran sodium sulfate-induced mouse model of ulcerative
colitis [104]. CLAY-001 is an inhibitor of MMP-9 enzymatic activity, whereas AB-0046-h4 inhibits the
activation of pro-MMP-9 which leads to decreased MMP-9 activity. Since both antibodies reduced
the disease severity in a mouse model of intestinal inflammation, they were assessed for antifibrotic
activity in an intestinal fibrosis model where they showed that inhibiting MMP-9 activity significantly
restrains fibrogenesis [20].
4.2. Anti-MMP-14 Antibodies
It has been proposed that MMP-14 plays a crucial role in pathological systems, such as tumor
growth, invasion, and neovascularization. It is able to cleave matrix proteins and it activates
proMMP-2, which leads to an amplification of pericellular proteolytic activity. Using phage display
technology, Devy et al. have discovered the highly selective human MMP-14 inhibitory antibody
DX-2400 [102]. It eciently blocks proMMP-2 activation and displays anti-invasive activity in vitro.
As MMP-14 is involved in physiologic and pathologic angiogenesis, its inhibition by DX-2400 exhibited
reduced angiogenesis through inhibition of VEGF-driven cell invasion and proMMP-2 activation.
In in vivo studies, the single agent or combination application of DX-2400 markedly aected growth
of MDA-MB-231 and BT-474 tumor cell lines. Pilot toxicology studies did not reveal any clinical
or histologic findings, including abnormalities of the joints, oering a promise that DX-2400 will
be tolerated in the clinic [102]. Further in vivo studies of murine breast tumor models showed that
MMP-14 blockade by DX-2400 decreased immunosuppressive TGF, polarized macrophages to an
antitumor phenotype, increased inducible nitric oxide synthase, and improved tumor perfusion,
resulting in reduced primary tumor growth and enhanced response to radiation therapy, especially in
high MMP-14 expressing tumors [107].
In 2013, Ingvarsen and Porse et al. described the monoclonal antibody 9E8 that selectively inhibits
a single function of the multifunctional MMP-14 [27]. The antibody completely blocks the ability
of MMP-14 to activate proMMP-2 without interfering with its proteolytic activity. Employing this
antibody, they could show that the MMP-14 catalyzed activation of proMMP-2 is involved in the
outgrow of cultured lymphatic endothelial cells in a collagen matrix in vitro, as well as in lymphatic
vessel sprouting ex vivo [27]. As the antibody does not interact with other members of the membrane
type MMP family, Shiryaev et al. examined the mechanism of this selectivity using mutagenesis,
binding and activity assays, and in silico modeling. They demonstrated that the 9E8 antibody recognizes
the membrane type loop structure distant from the active site [33].
In comparison to the above mentioned antibodies (DX-2400 and 9E8) which inhibit the proMMP-2
activating function of MMP-14 while leaving the proteolytic function untouched, Udi et al. published
LEM-2/15 that inhibits the collagenolytic function of MMP-14 selectively [34]. It inhibits the cleavage
of the native substrates, collagen type I and gelatin. As within the MMP family, the members vary in
terms of the nature of the V-B loop residues, and the LEM-2/15 antibody was generated by immunizing
mice with a cyclic peptide that mimics the corresponding sequence in MMP-14. For easier handling,
they generated a minimized antibody fragment that inhibited MMP-14 catalytic domain with an IC50
of 45 nM. Kinetic analyses for the determination of the inhibition type showed a noncompetitive
inhibition pattern and the finding that Fab LEM-2/15 did not compete with the substrate binding at the
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catalytic center indicated that Fab LEM-2/15 modulates the catalytic activity allosterically by binding at
the V-B loop away from the active site. Structural comparison of the free Fab fragment and complexed
to a segment of MMP-14, as in Figure 8, suggests a major conformational change of the protease while
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(PDB ID: 4P3D) [34] and right: the loop conformation of MMP-14 bound to TIMP-1 (PDB ID: 3MA2) [84].
The observed conformational change can explain the inhibition due to allosteric modification of the
enzyme structure.
This conformational change leads to narrowing of the substrate-binding cleft, which delivers an
explanation for the inhibition of the collagenolytic function as it prevents substrate binding. As in
some stages of cancer progression MMP-2 represents an anti-target, and activation of proMMP-2 is
beneficial, the collagenolytic activity of MMP-14 remains a target to address and LEM-2/15 could serve
as a potential novel therapeutic [34].
Nam et al. synthesized a human Fab antibody library in which they varied the complementarity
determining region (CDR)-H3 by implementing an extended segment [108]. The strategy evoked from
analyzing known camelid inhibitory antibodies, which contain long and convex-shaped paratopes
that penetrate into the catalytic cleft for the inhibition of the enzymatic activity. In the study, 23- to
27-residues long CDR-H3s were synthesized for the putative formation of the convex-shaped paratopes.
The constructed CDR-H3s, in contrast to the normal length CDR-H3s, displayed inhibition of MMP-14.
Inhibitory antibody Fab 3A2 with a 27-residue long CDR-H3 modification proved highly ane to the
target enzyme, with a Kd of 4.85 nM that inhibited MMP-14 with an IC50 of 9.7 nM, which is in the
same order of magnitude as the endogenous TIMP-2 (5.1 nM) and the hydroxamate based non selective
inhibitor GM6001 (2.1 nM). It was suggested that Fab 3A2 targets the S1’ pocket within MMP-14 and
competes with TIMP-2 and the substrate without reaching out to the catalytic zinc(II) ion [32,108].
As Fab 3A2 can be cleaved by high concentrations of MMP-14, mutations were introduced that vary in
the positions adjacent to the cleavage site, which led to more stable mutants with prolonged half-life
and high potency [109,110]. In a syngeneic mouse breast cancer model with fast and spontaneous
metastasis, IgG 3A2 displayed significant impact on tumor growth as well as metastatic spread and
proved its therapeutic potential [25]. The strategy of synthesizing convex paratope antibody libraries
might also facilitate the design of inhibitory antibodies for other enzymes in the future [108]. In the
same group, they have obtained a highly ane (EC50 = 8.3 nM) and selective inhibitory antibody for
the inhibition of MMP-14 by grafting a cyclic peptide motif GACFSIAHECGA (Peptide G), previously
identified as a selective inhibitor [111], into the complementarity determining region (CDR) of an
antibody scaold [31]. The Fab 1F8 inhibited MMP-14 with a Ki-value of 110 nM, which is, by three
orders of magnitude, more potent than the Peptide G with 150 M.
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Recently, Ling et al. disclosed IgG 3369 and Fab 3369 deriving from screening a phage displayed
synthetic humanized Fab library [29]. Fab 3369 is with an IC50 of 62 nM against MMP-14 similarly
potent as the hydroxamate based broad-spectrum inhibitors and was therefore used as a lead inhibitory
antibody for further investigations. In an in vitro assay with MDA-MB-231 cells, Fab 3369 was able to
block endogenous MMP-14 expressed on the cell surface, and to inhibit extracellular matrix degradation
and triple-negative breast cancer (TNBC) cell invasion. For continuing experiments, they employed
the clone as a human IgG1 and tested it in mammary orthotopic xenograft assays using MDA-MB-231
cells injected in mice lacking NK (natural killer), B, and T cells. Mice treated with IgG 3369 showed a
significant reduction in tumor growth and reduced tumor mass at the endpoint. The IgG and vector
control groups revealed more lung metastases compared to the IgG 3369 treated or the MMP-14
knock-down group. The blockade of MMP-14 by IgG 3369 also disrupts the hypoxic TNBC tumor
microenvironment leading to tumors with reduced density, and it impairs tumor progression and
metastasis in a syngeneic breast cancer model.
5. Conclusions
This review highlights the emerging field of designing inhibitory antibodies for the selective
inhibition of matrix metalloproteinases. The MMP family has been an intriguing target class for
pharmaceutical researchers in academia and in industry for almost three decades. The first peak of
interest resulted in a flood of small molecule inhibitors that did not discriminate between the individual
members, resulting in failed clinical trials due to intolerable side eects. Further development gave
rise to more selective small molecule inhibitors that inhibited only one member or a small subset of the
target class, but until today, none of them have reached the market. Major setbacks such as toxicity,
lack of selectivity, or therapeutic ecacy have impeded their advancement.
Therefore, alternatives are needed and the development of inhibitory antibodies that specifically
target one single MMP hold great promise as future therapeutics. Although this field is still very
young and there will certainly be many more inhibitory antibodies against individual MMPs in the
future, outstanding results have already been achieved. The potent and highly selective antiMMP-9
monoclonal antibody GS-5747 displayed positive eects in the treatment of ulcerative colitis and
gastric cancer. A combination study of GS-5745 with mFOLFOX6 currently investigates the ecacy
and safety in patients with untreated gastric and gastroesophageal junction adenocarcinoma in a phase
III clinical trial. With the latest successes in the field, the probability increased significantly that a
drug will be developed that targets this enzyme family and enables clinical ecacy in the treatment of
MMP-related diseases.
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